Suppr超能文献

种族差异与淀粉样蛋白阳性率和认知轨迹。

Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories.

机构信息

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.

Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea.

出版信息

Alzheimers Dement. 2024 Nov;20(11):7556-7566. doi: 10.1002/alz.14247. Epub 2024 Sep 24.

Abstract

INTRODUCTION

We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs).

METHODS

We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants underwent Aβ positron emission tomography and were categorized into cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia stages. Age, sex, education, and apolipoprotein E. genotype were adjusted using multivariable logistic regression and stabilized inverse probability of treatment weights based on the propensity scores to mitigate imbalances in these variables.

RESULTS

The prevalence of Aβ+ was lower in CU Koreans than in CU NHWs (adjusted odds ratio 0.60). Aβ+ Koreans showed a faster cognitive decline than Aβ+ NHWs in the CU (B = -0.314, p = .004) and MCI stages (B = -0.385, p < .001).

DISCUSSION

Ethnic characteristics of Aβ biomarkers should be considered in research and clinical application of Aβ-targeted therapies in diverse populations.

HIGHLIGHTS

Koreans have a lower prevalence of Aβ positivity compared to NHWs in the CU stage. The effects of Alzheimer's risk factors on Aβ positivity differ between Koreans and NHWs. Aβ-positive (Aβ+) Koreans show faster cognitive decline than Aβ+ NHWs in the CU and MCI stages.

摘要

简介

我们研究了韩国人和非西班牙裔白人(NHW)中β淀粉样蛋白(Aβ)阳性(+)的流行率和认知轨迹。

方法

我们纳入了来自韩国多个中心的 5121 名韩国人和来自阿尔茨海默病神经影像学倡议(ADNI)的 929 名 NHW。参与者接受了 Aβ 正电子发射断层扫描,并分为认知正常(CU)、轻度认知障碍(MCI)和痴呆阶段。使用多变量逻辑回归和基于倾向评分的稳定逆概率治疗权重调整年龄、性别、教育程度和载脂蛋白 E 基因型,以减轻这些变量的不平衡。

结果

CU 韩国人的 Aβ+患病率低于 CU NHW(调整后的优势比 0.60)。与 Aβ+ NHW 相比,Aβ+韩国人在 CU(B=-0.314,p=0.004)和 MCI 阶段(B=-0.385,p<0.001)的认知下降更快。

讨论

在不同人群中进行 Aβ 靶向治疗的研究和临床应用时,应考虑 Aβ 生物标志物的种族特征。

要点

与 CU 阶段的 NHW 相比,韩国人的 Aβ 阳性率较低。阿尔茨海默病风险因素对 Aβ 阳性的影响在韩国人和 NHW 之间存在差异。Aβ+韩国人在 CU 和 MCI 阶段的认知下降速度快于 Aβ+NHW。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/953d/11567875/5a5ae6241146/ALZ-20-7556-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验